Spotlight On... Khosla backs Neurotrack in $6.5M as it launches web-based, eye-tracking cognitive test; Edwards gives grant to Fogarty Institute; FDA nod for modified needle-free blood draw device; and more...

Palo Alto, CA's Neurotrack launched its first product, the Imprint, a digital cognitive assessment test for the evaluation of patients who may be at risk for cognitive decline. The goal is to advance research and treatment of cognitive diseases like Alzheimer's. In addition, the company reported $6.5 million in new funding, led by Khosla Ventures and supported by Social Capital, Founders Fund, AME Cloud Ventures and iSeed Ventures. The web-based test takes 5 minutes and utilizes eye-tracking technology to assess recognition memory and hippocampal impairment. Release

@FierceMedDev: Israeli VC backed by Philips and Teva looking to invest $26M in promising med tech startups. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+. Article | Follow @VarunSaxena2

@EmilyWFierce: Dog flu sweeps the U.S. with two more confirmed cases in Washington state. FierceAnimalHealth story | Follow @EmilyWFierce

> Edwards Lifesciences ($EW) has granted almost a half a million dollars to medical device incubator the Fogarty Institute for Innovation toward the financing of new med tech startups. More

> The FDA has cleared a modified version of the needle-free blood draw for hospital patients that it had already approved. The device works via an existing peripheral IV catheter. More

> Admetsys and Hospira have partnered on an artificial pancreas; the Admetsys device will use injectable dextrose from Hospira to enable more precise glucose control to protect from hypoglycemic episodes during hospitalization. More

Biotech News

@FierceBiotech: UT Southwestern team IDs next-gen approach to fighting pancreatic cancer. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Turn out the lights, the party is over: Gov't finds Theranos lab poses 'immediate jeopardy to patient safety.' CNBC article | Follow @JohnCFierce

> Neos wins FDA approval for a melts-in-your-mouth take on Adderall for ADHD. Article

> The top 10 (possible) blockbusters that (might) launch this year. More

> Venetoclax grabs third FDA 'breakthrough' for blood cancer. Report

Pharma News

@FiercePharma: No obvious China baby bump for J&J as one-child policy ends. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: Novartis is revamping its manufacturing after having disposed of 25 plants. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI: U.K. cost watchdog nixes pricey biologics for moderate rheumatoid arthritis. Article | Follow @CarlyHFierce

> Riding Q4 diabetes growth, Lilly aims for even more with Jardiance. Report

> State AG's protest against Gilead pricing destined to fail, legal observers suggest. Story

> Big investor pushes 'underperforming' J&J to step up or split up. Article

CRO News

> PRA recruits a U.K. marketing firm to help it reach more patients. Report

> In the midst of cuts, Parexel signs new research deal. More

> Parexel dims its revenue expectations despite a solid quarter. Story

> Icon launches new tech with promise to simplify adaptive trials. News

> BioClinica notches up another deal, this time with EPS. Article

Pharma Manufacturing News

> Lilly closing two animal health manufacturing plants picked up from Novatis. Article

> Baxter recalls saline, other products, contaminated by cardboard, cloth and skin. News

> Novartis revamping manufacturing after hiving off 25 plants. More

> GSK production coming up short for meningitis B vax, causing some shortages. Item

> Recipharm wrapping up its $105M deal for Indian sterile injectables maker Nitin. Article

Pharma Asia News

> India's Supreme Court allows Cipla move in Roche patent case. News

> Sino Biopharma's asset management deal drawing negative reviews. Report

> 3SBio buys a larger stake in CP Guojian Pharma for $150M. Story

> Novartis expects India's Sun to meet February U.S. generic Gleevec launch. More

> Another legal test for U.S. in case of Chinese scientists accused of stealing GSK secrets. Article